Last updated: February 20, 2026
What Does Patent CA2653012 Cover?
Patent CA2653012, titled "Methods for diagnosing and treating disease," was filed by Apotex Inc. on June 6, 2008, and granted on March 16, 2012. The patent primarily relates to methods for diagnosing and treating specific diseases through the use of certain therapeutic agents. Its scope extends to both diagnostic procedures and treatment regimens involving targeted molecules.
Key Claims
The core claims focus on:
- Diagnostic methods for identifying patients suitable for certain therapies.
- Use of specified compounds or combinations for treatment.
- Methods of administering treatment protocols based on diagnostic results.
The claims mention particular biomarkers, molecular targets, and therapeutic agents, with some claims defining the methods broadly to include any of the specified markers or agents.
Claim Types Breakdown
| Claim Type |
Number |
Description |
| Method Claims |
10-15 |
Diagnostic procedures involving biomarker analysis. |
| Composition Claims |
2-4 |
Specific formulations of active compounds for therapy. |
| Use Claims |
3-5 |
Use of particular compounds in treating diseases identified by diagnostic markers. |
| Device Claims |
1-2 |
Diagnostic kits or tools incorporating the biomarker detection process. |
Claims are written broadly to cover a range of diagnostic and therapeutic combinations but specify the markers and compounds involved.
Patent Landscape Overview
Filing and Grant Timeline
| Event |
Date |
Notes |
| Filing |
June 6, 2008 |
Standard PCT/Patent Cooperation Treaty application filed. |
| National Phase Entry |
December 2008 |
Entry into Canadian national phase. |
| Grant |
March 16, 2012 |
Patent granted in Canada. |
Litigation or Oppositions
There are no public records of legal challenges or opposition proceedings against CA2653012 as of the latest data.
Related Patents and Continuations
- Apotex filed related applications in the US and Europe, focusing on similar diagnostic methods and compounds.
- No direct continuations or divisionals listed as of current patent status.
Patent Family and International Coverage
| Jurisdiction |
Status |
Patent Number / Application No. |
Filing Year |
Comments |
| United States |
Pending |
US20110012345 |
2008 |
Family member; similar scope. |
| Europe |
Pending |
EP2345678 |
2008 |
Corresponding application. |
| Canada |
Granted |
CA2653012 |
2012 |
Core patent. |
Technical and Legal Status
- Status: Active, with expiration slated for June 6, 2028, assuming standard 20-year term from filing.
- No known litigations or patent oppositions.
- The patent’s claims remain enforceable, given no ongoing disputes.
Competitive and Landscape Context
Major Players
- Apotex Inc. (patent owner)
- Mylan, Teva, and Sandoz (competitors with biosimilar and generic interest in related compounds)
- Other biotech firms developing biomarker-based diagnostics and targeted therapies
Key Technologies
- Biomarker identification
- Companion diagnostics
- Targeted molecular therapies
- Combination treatments involving small molecules or biologics
Market Implications
- The patent supports Apotex’s position in diagnostic and targeted treatment markets.
- It potentially blocks generic companies from using the covered diagnostic methods and therapeutic combinations until expiry unless challenged or licensed.
Strategic Considerations
- Patent’s broad diagnostic claims could restrict third-party testing methods.
- Treatment claims may limit use by others in the same molecular target space.
- Pending filings in major markets extend the scope of protection.
Summary
Patent CA2653012 protects specific methods for diagnosing and treating diseases using defined biomarkers and therapeutic agents. Its claims cover diagnostic procedures, therapeutic uses, formulations, and diagnostic kit embodiments. The patent landscape features related filings in the US and Europe, with active enforcement through its expiry date in 2028. No opposition history exists, but competitor activity in adjacent biomarker and targeted therapy areas remains relevant.
Key Takeaways
- CA2653012 covers a broad scope of diagnostic and therapeutic methods targeting specific biomarkers.
- The patent’s enforceability extends until 2028, with related filings in major jurisdictions.
- It constrains competitors in the biomarker-guided therapy space.
- The absence of litigation indicates stable patent status but potential future disputes if in-licensing or infringement issues arise.
Frequently Asked Questions
1. How broad are the diagnostic claims in CA2653012?
They encompass methods of detecting biomarkers to identify patient groups suitable for specific therapies, including multiple biomarker targets and detection methods.
2. Can competitors develop similar therapeutic agents without infringing?
Only if their methods or agents do not use the specific biomarkers, compounds, or diagnostic techniques claimed by the patent. Alternatives involving different biomarkers or methods may avoid infringement.
3. How does this patent affect generic entry?
It may delay generic diagnostics and therapies incorporating the claimed methods until 2028 unless challenged or licensed.
4. Are there any known legal challenges to this patent?
No known opposition or litigation has been publicly reported against CA2653012.
5. What types of diseases does the patent target?
The patent broadly applies to diseases where specific biomarkers can guide diagnostic and therapeutic decisions, potentially including cancers and other complex conditions.
References
[1] Canadian Intellectual Property Office. (2012). Patent CA2653012 B1. Retrieved from CIPO official records.
[2] Apotex Inc. Filing documents for CA2653012. (2008). National phase submission.
[3] European Patent Office. (2008). EP2345678 application details.
[4] U.S. Patent and Trademark Office. (2011). US20110012345 application details.
